Topical Sirolimus for Darier Disease: a Multicentre Case Series and Immunostaining of Patient Biopsies Implicating mTORC1-associated Signalling
BACKGROUND: Darier disease (DD) is caused by pathogenic ATP2A2 variants that impair calcium homeostasis and keratinocyte adhesion. Responses to MEK inhibition support investigating additional pathway-directed treatments. Phosphorylated ribosomal protein S6 (pS6) Ser240/244 provides a downstream readout of mTORC1-associated signalling. OBJECTIVES: To describe outcomes with topical sirolimus 1% in DD and quantify epidermal pS6 Ser240/244 in paired lesional and non-lesional skin and healthy controls. METHODS: We retrospectively reviewed six patients treated with compounded sirolimus 1% cream, including three who received it as an add-on to ongoing systemic therapy. Treated areas were assessed using a retrospective Physician Global Assessment (PGA). Epidermal pS6 Ser240/244 immunofluorescence was quantified in nine pairs of lesional and non-lesional DD biopsies and nine healthy-control biopsies, using one aggregate value per biopsy. RESULTS: All five evaluable patients showed symptomatic and/or clinical improvement at a median PGA assessment time of 1 month (range 10 days to 6 weeks). One patient discontinued treatment after three days because of local intolerance, precluding efficacy assessment. Mean (SD) corrected pS6 intensity was 10.3 (2.0) arbitrary units in controls, 60.0 (53.5) in non-lesional DD and 99.5 (41.2) in lesional DD. Both DD groups differed from controls (Holm-adjusted P = 0.00185 and P = 0.0000823, respectively). Non-lesional values were heterogeneous, and the paired lesional-non-lesional difference was not significant (P = 0.36). CONCLUSIONS: Topical sirolimus showed promise as a local treatment, including as an adjunct for persistent lesions during systemic therapy. Increased epidermal pS6 provides complementary biological support for investigating mTORC1 inhibition in DD.
Authors
- África González‐Fernández (ORCID: https://orcid.org/0000-0002-9226-4825)
- Maria-Elena Gimeno-Ribes
- Andrea Hernández-Fernández
- Diego Soto‐García (ORCID: https://orcid.org/0000-0001-6559-3108)
- Catherine Tomé-Espiñeira
- Nuria No
- Or Haskel (ORCID: https://orcid.org/0000-0001-6289-9099)
- Ignacio García-Doval (ORCID: https://orcid.org/0000-0002-6881-5260)
- P. Dávila‐Seijo (ORCID: https://orcid.org/0000-0001-5820-8961)
- Andrea Fernández‐Carrera (ORCID: https://orcid.org/0000-0002-6442-4852)
- Sandra Martínez‐Fernández (ORCID: https://orcid.org/0000-0003-4534-7828)
- Roni P. Dodiuk‐Gad (ORCID: https://orcid.org/0000-0003-2168-3798)
- Ainhoa Rodríguez-Tébar (ORCID: https://orcid.org/0000-0003-4365-3119)
- Cristian Sánchez-Espinel
- Eulalia Baselga
- Aranzazu Vergara Sánchez
- María del Carmen Fraile-Alonso
- M Begoña Iglesias Rodríguez
Institutions
- Hospital Sant Joan de Déu Barcelona (ES)
- Technion – Israel Institute of Technology (IL)
- Universidad de Salamanca (ES)
- University of Toronto (CA)
- Emek Medical Center (IL)
- University Hospital Complex Of Vigo (ES)
- Hospital Universitario de Guadalajara (ES)
- Complejo Hospitalario de Salamanca (ES)
- Servicio Gallego de Salud (ES)
- Complejo Hospitalario de Pontevedra (ES)
- Universidade de Vigo (ES)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1093/bjd/ljag491
- Primary Topic
- Genetic and rare skin diseases.
- Type
- article
- Field-Weighted Citation Impact
- 0.00